Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
They could both outperform the market over the medium term, but one appears to have a clear edge.
Overview
The biotech industry is experiencing a strong rebound in 2026 after lagging the market in recent years. Based on several ongoing developments -- including breakthroughs in oncology and chronic weight management -- we may see a sustained run from the industry over the next few years. Even if we don't, several individual biotech companies look like strong medium-term options right now, including Vertex Pharmaceuticals (NASDAQ: VRTX) and Regeneron (NASDAQ: REGN). There is a lot to like about both of these drugmakers, but which one is the better buy? Let's find out.
Image source: The Motley Fool.
Vertex Pharmaceuticals doesn't have a long list of products like many of its similarly sized peers in the biotech industry. That's because it doesn't need to. The company famously dominates the market for cystic fibrosis (CF) drugs, a rare disease that causes difficulty breathing and recurrent infections.
Details
Source
Originally published at www.fool.com.